Updated:
May 25, 2021 19:12 IST
The vaccine manufacturer announced that its COVID-19 vaccine mRNA-1273 is 100% effective in preventing symptomatic infections in 12-17 year olds after two doses
Share Article
AAA
U.S. biotech firm Moderna said on May 25, 2021 that trials had shown its COVID-19 vaccine is "highly effective" in adolescents aged 12-17 and the company would seek regulators' approval in June.
| Photo Credit:
AFP
The vaccine manufacturer announced that its COVID-19 vaccine mRNA-1273 is 100% effective in preventing symptomatic infections in 12-17 year olds after two doses
The possibility of children returning to normal life in the U.S. became stronger on Tuesday with vaccine manufacturer Moderna announcing that its COVID-19 vaccine mRNA-1273 is 100% effective in preventing symptomatic infections in 12-17 year olds after two doses. The company said that it would approach the Food and Drug Administration (FDA) to extend the use of its vaccine to this age group, in early June.